诊断对前蛋白转化酶枯草杆菌蛋白酶/克新9型抑制剂的耐药性。 - Suppr

Suppr

超能文献

Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor.

作者信息

Shapiro Michael D, Miles Joshua, Tavori Hagai, Fazio Sergio

机构信息

Oregon Health & Science University, Portland, Oregon (M.D.S., J.M., H.T., S.F.).

出版信息

Ann Intern Med. 2018 Mar 6;168(5):376-379. doi: 10.7326/M17-2485. Epub 2017 Nov 28.

DOI:10.7326/M17-2485

PMID:29181527

Abstract

摘要

相似文献

Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor.诊断对前蛋白转化酶枯草杆菌蛋白酶/克新9型抑制剂的耐药性。

Ann Intern Med. 2018 Mar 6;168(5):376-379. doi: 10.7326/M17-2485. Epub 2017 Nov 28.

CardioPulse: The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors.《心脏脉搏》：欧洲药品管理局对前蛋白转化酶枯草溶菌素/克新9型抑制剂的批准

Eur Heart J. 2016 Feb 7;37(6):502-3. doi: 10.1093/eurheartj/ehv685.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.前蛋白转化酶枯草溶菌素/kexin 9型（PCSK9）抑制剂。一种用于治疗高胆固醇血症的新型药物类别。

Endocrinol Diabetes Nutr. 2017 Aug-Sep;64(7):341-344. doi: 10.1016/j.endinu.2017.04.005. Epub 2017 Jun 3.

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.欧洲心脏病学会/欧洲动脉粥样硬化学会前蛋白转化酶枯草溶菌素9型抑制剂在动脉粥样硬化性心血管疾病患者或家族性高胆固醇血症患者中应用的实用临床指南工作组2017年更新版

Eur Heart J. 2018 Apr 7;39(14):1131-1143. doi: 10.1093/eurheartj/ehx549.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.用于治疗高胆固醇水平的前蛋白转化酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂：有效性和价值。

JAMA Intern Med. 2016 Jan;176(1):107-8. doi: 10.1001/jamainternmed.2015.7248.

Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.前蛋白转化酶枯草溶菌素/kexin 9型抑制剂在高胆固醇血症治疗中的应用

Endocrinol Nutr. 2016 Jun-Jul;63(6):255-7. doi: 10.1016/j.endonu.2016.02.002. Epub 2016 Apr 1.

Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.家族性高胆固醇血症患者的血浆前蛋白转化酶枯草溶菌素/凝血酶 9 浓度与复发性心血管事件。

Eur J Prev Cardiol. 2021 Apr 23;28(3):272-279. doi: 10.1177/2047487319880985. Epub 2019 Oct 11.

[Up to date lipid lowering treatment].[最新降脂治疗]

Orv Hetil. 2016 Jul;157(31):1219-23. doi: 10.1556/650.2016.30505.

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.载脂蛋白 B 代谢物单克隆抗体 AMG 145 降低杂合子家族性高胆固醇血症患者低密度脂蛋白胆固醇的作用：载脂蛋白 B 代谢物单克隆抗体 AMG 145 降低杂合子家族性高胆固醇血症患者低密度脂蛋白胆固醇的随机试验（RUTHERFORD）

Circulation. 2012 Nov 13;126(20):2408-17. doi: 10.1161/CIRCULATIONAHA.112.144055. Epub 2012 Nov 5.

Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?前蛋白转化酶枯草溶菌素9型（PCSK9）抑制剂与心血管风险：对傅里叶试验的进一步分析是否提示降脂治疗靶点的变化？

High Blood Press Cardiovasc Prev. 2018 Mar;25(1):5-7. doi: 10.1007/s40292-017-0244-x. Epub 2018 Jan 5.

引用本文的文献

Inadequate Response to PCSK9 Inhibitors.对前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂反应不足。

JACC Case Rep. 2025 Apr 16;30(8):103696. doi: 10.1016/j.jaccas.2025.103696.

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials.前蛋白转化酶枯草溶菌素/克新9型抑制剂对脂蛋白(a)的影响：随机对照试验的荟萃分析和荟萃回归

JACC Adv. 2025 Jan 10;4(2):101549. doi: 10.1016/j.jacadv.2024.101549. eCollection 2025 Feb.

Therapeutic Persistence in the Management of Familial Hypercholesterolemia: A Case of Acquired PCSK9 Inhibitor Nonresponse.家族性高胆固醇血症管理中的治疗持续性：一例获得性PCSK9抑制剂无反应病例

JACC Case Rep. 2024 Dec 4;29(23):102712. doi: 10.1016/j.jaccas.2024.102712.

Cholesterol reduction by immunization with a PCSK9 mimic.通过免疫接种 PCSK9 模拟物降低胆固醇。

Cell Rep. 2024 Jun 25;43(6):114285. doi: 10.1016/j.celrep.2024.114285. Epub 2024 May 30.

Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review.降低低密度脂蛋白胆固醇的药物：一篇叙述性综述

J Clin Med. 2024 Feb 7;13(4):943. doi: 10.3390/jcm13040943.

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.靶向前蛋白转化酶枯草溶菌素 9（PCSK9）：从实验室到临床。

Signal Transduct Target Ther. 2024 Jan 8;9(1):13. doi: 10.1038/s41392-023-01690-3.

Genetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative Review.注射用降脂药物的遗传学、安全性、成本效益及可及性：一项叙述性综述

J Lipids. 2023 Mar 8;2023:2025490. doi: 10.1155/2023/2025490. eCollection 2023.

PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection.PCSK9 抑制剂之战：依洛尤单抗与当前单克隆抗体抑制剂治疗相比如何？患者选择的考虑因素。

Curr Cardiol Rep. 2022 Nov;24(11):1657-1667. doi: 10.1007/s11886-022-01782-6. Epub 2022 Sep 10.

PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid-Based Therapy Era.PCSK9 单克隆抗体：新进展及其在基于核酸的治疗时代的相关性。

Curr Atheroscler Rep. 2022 Oct;24(10):779-790. doi: 10.1007/s11883-022-01053-3. Epub 2022 Jul 28.

The promising novel therapies for familial hypercholesterolemia.家族性高胆固醇血症的有前途的新型疗法。

J Clin Lab Anal. 2022 Jul;36(7):e24552. doi: 10.1002/jcla.24552. Epub 2022 Jun 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验